|Project Title||Principal Investigator||Institution|
|Vasopressin receptors and social attachment||Young, Larry||Emory University|
|Functional study of synaptic scaffold protein SHANK3 and autism mouse model||Jiang, Yong-Hui||Duke University|
|Neurogenetic model of social behavior heterogeneity in autism spectrum disorders||Platt, Michael||Duke University|
|Role of UBE3A in neocortical plasticity and function||Ehlers, Michael||Duke University|
|Investigating the effects of chromosome 22q11.2 deletions||Karayiorgou, Maria||Columbia University|
|Genomic imbalances at the 22q11 locus and predisposition to autism||Gogos, Joseph||Columbia University|
|Analysis of cortical circuits related to ASD gene candidates||Zador, Anthony||Cold Spring Harbor Laboratory|
|Novel models to define the genetic basis of autism||Mills, Alea||Cold Spring Harbor Laboratory|
|Systematic analysis of neural circuitry in mouse models of autism||Osten, Pavel||Cold Spring Harbor Laboratory|
|16p11.2: defining the gene(s) responsible||Mills, Alea||Cold Spring Harbor Laboratory|
|Novel probiotic therapies for autism||Patterson, Paul||California Institute of Technology|
|Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders -2||Nakanishi, Nobuki||Burnham Institute|
|Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders - 1||Lipton, Stuart||Burnham Institute|
|Characterization of autism susceptibility genes on chromosome 15q11-13||Smith, Stephen||Beth Israel Deaconess Medical Center|
|Neurobiological mechanism of 15q11-13 duplication autism spectrum disorder||Anderson, Matthew||Beth Israel Deaconess Medical Center|
|Identifying genetic modifiers of rett syndrome in the mouse||Buchovecky, Christine||Baylor College of Medicine|
|Modeling and pharmacologic treatment of autism spectrum disorders in Drosophila||McDonald, Thomas||Albert Einstein College of Medicine of Yeshiva University|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
IACC Recommended Budget: $75,000,000 over 5 years
|4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 90 projects were supported to develop animal models.
Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.